Last reviewed · How we verify
Ampicillin Injection
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, meningitis, endocarditis, septicemia), Prophylaxis in surgical procedures.
At a glance
| Generic name | Ampicillin Injection |
|---|---|
| Sponsor | Far Eastern Memorial Hospital |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ampicillin works by disrupting the formation of the bacterial cell wall, which is essential for bacterial survival and structural integrity. By inhibiting peptidoglycan synthesis, the drug causes cell wall weakening and bacterial lysis. This bactericidal mechanism is effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, meningitis, endocarditis, septicemia)
- Prophylaxis in surgical procedures
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / Anaphylaxis
- Pseudomembranous colitis
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients (NA)
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ampicillin Injection CI brief — competitive landscape report
- Ampicillin Injection updates RSS · CI watch RSS
- Far Eastern Memorial Hospital portfolio CI